vendredi 11 novembre 2011

Press review (November 12, 2011) – Revue de presse (12 novembre 2011)




Cancer treatment shows promise for rapid weight loss
A synthetic peptide that inhibits blood supply, a strategy employed in many cancer drugs, is found to kill fat cells and improve metabolic function in trials involving monkeys.
By Melissa Healy. In Los Angeles Times

'Epigenetic' therapy shows promise for hard-to-treat lung cancer
A new 'epigenetic' therapy appears to be able to prolong the life of patients with late-stage non-small cell lung cancer (NSCLC), according to the results of a small clinical trial published in the journal Cancer Discovery.
In Cancer Research UK

Computer 'pathologist' could assess breast cancer survival
A new computer model analyzes microscopic breast cancer images and predicts patient survival better than the pathologists who do the job now, new research suggests.
By Kathleen Doheny. USA Today

Roche skin cancer drug to get priority review in U.S
Roche's experimental skin cancer drug vismodegib has been given "priority review" status by U.S. authorities, the Swiss drugmaker said on Wednesday.
Reuters

More Evidence That HPV Vaccine Shields Against Cervical Cancer
Coverage against precancerous lesion called 'excellent' in large, multinational study.
In U.S. News & World Report

Bavarian Nordic's Immunotherapy Product Candidate CV-301 Shows Promise in Breast and Ovarian Cancer
Bavarian Nordic A/S (OMX: BAVA) today announced that encouraging clinical trial results with CV-301 in patients with metastatic breast or ovarian cancer were published in Clinical Cancer Research, a peer-reviewed journal of the American Association for Cancer Research. Through an expanded collaboration with the National Cancer Institute (NCI) and license with the National Institutes of Health (NIH), the Company obtained rights to CV-301, an off-the-shelf cancer immunotherapy product candidate for multiple cancers, in October 2011.
Reuters

Screening For Several Cancer-Causing Genetic Mutations
For the first time, investigators in the U.S. have demonstrated that it is possible to screen individuals with cancer for a variety of cancer-causing genetic mutations as part of normal clinical practice. Doctors have the ability to target tumors with the most suitable treatment by identifying patients' individual genotypes within a fairly short time period.
By Grace Rattue. In Medical News Today

UK cost body rules against AstraZeneca cancer drug
AstraZeneca's breast cancer drug Faslodex has been rejected for use on Britain's state health service, dealing a blow to a product that has been on the market in Europe since 2004.
Reuters

UT MD Anderson study finds acupuncture can prevent radiation-induced chronic dry mouth
When given alongside radiation therapy for head and neck cancer, acupuncture has shown for the first time to reduce the debilitating side effect of xerostomia, according to new research from The University of Texas MD Anderson Cancer Center and Fudan University Shanghai Cancer Center.
In EurekAlert

Cancer : les perturbateurs endocriniens sur la sellette
L'Académie de médecine reconnaît la nocivité probable du bisphénol A ou des parabènes mais juge «irréalisable» leur interdiction tant que la fiabilité des produits de remplacement n'a pas été prouvée.
Par Marc Mennessier. Dans Le Figaro

Cancer du sein: augmentation des ablations mammaires sauf chez les 50-74 ans
Le taux de mastectomies totales, ou ablation d'un sein pour traiter un cancer, a tendance à augmenter depuis 2005, excepté parmi les femmes de 50 à 74 ans, selon une étude présentée mercredi à Marseille au congrès de la Société de sénologie.
AFP

Adopter la moustache contre le cancer de la prostate‎‎
Lancée comme une blague en 2004, la campagne de prévention «Movember» rencontre un succès grandissant dans le monde anglo-saxon.
Par Cyrille Vanlerberghe. Dans Le Figaro


La thérapie épigénétique testée dans le cancer du poumon
La thérapie épigénétique a donné des résultats prometteurs chez quelques patients ayant un cancer du poumon métastasé réfractaire : elle a allongé la survie moyenne et des réponses remarquables ont été observées chez une petite fraction des patients.
Le Quotidien du Médecin

Cancer de la peau: procédure d'homologation accélérée au Etats-Unis pour un médicament
L'autorité américaine des médicaments (FDA) a accordé au médicament Vismodegib, destiné à traiter certaines formes de cancer de la peau, une procédure d'homologation accélérée, a indiqué mercredi le groupe pharmaceutique suisse Roche.
AFP

Aucun commentaire:

Enregistrer un commentaire